Literature DB >> 9597213

Re-evaluation of i.m. ephedrine as prophylaxis against hypotension associated with spinal anaesthesia for Caesarean section.

A A Webb1, E A Shipton.   

Abstract

PURPOSE: To assess the safety and efficacy of 37.5 mg ephedrine i.m. in preventing hypotension associated with spinal anaesthesia for Caesarean section.
METHODS: In a double-blind randomised controlled study, 40 patients (20 in each group) were given either 37.5 mg ephedrine or placebo i.m. The following parameters were recorded: (i) blood pressure; (ii) heart rate; (iii) ephedrine i.v. supplementation; (iv) umbilical venous blood gases and neonatal Apgar scores.
RESULTS: The incidence of hypertension in the study group was 30% compared with 20% for the control group (P:NS). There was no difference in mean highest blood pressure or mean highest heart rate between the groups. The incidence of hypotension was lower but not significantly lower in the study group (50%) than in the control group (80%) (P:NS). However, the incidence of delayed hypotension was only 10% in the study group patients compared with 50% in the control group patients (P < 0.05).
CONCLUSION: Giving 37.5 mg ephedrine i.m. prior to spinal anaesthesia was not associated with reactive hypertension or tachycardia. Intramuscular ephedrine provided more sustained cardiovascular support than intravenous ephedrine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597213     DOI: 10.1007/BF03012030

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  9 in total

Review 1.  [Recent standards in management of obstetric anesthesia].

Authors:  Maximiliaan van Erp; Clemens Ortner; Stefan Jochberger; Klaus Ulrich Klein
Journal:  Wien Med Wochenschr       Date:  2017-07-25

Review 2.  [Ephedrine as alternative to Akrinor in regional obstetric anesthesia].

Authors:  L Aniset; C Konrad; M Schley
Journal:  Anaesthesist       Date:  2006-07       Impact factor: 1.041

3.  Efficacy of preanesthetic intramuscular administration of ephedrine for prevention of anesthesia-induced hypotension in cats and dogs.

Authors:  Christine Egger; Mary-Ann McCrackin; Erik Hofmeister; Gwenola Touzot-Jourde; Bart Rohrbach
Journal:  Can Vet J       Date:  2009-02       Impact factor: 1.008

4.  Techniques for preventing hypotension during spinal anaesthesia for caesarean section.

Authors:  Cheryl Chooi; Julia J Cox; Richard S Lumb; Philippa Middleton; Mark Chemali; Richard S Emmett; Scott W Simmons; Allan M Cyna
Journal:  Cochrane Database Syst Rev       Date:  2020-07-01

5.  Postspinal hypotension in elderly patients undergoing orthopedic surgery, prophylactic ephedrine versus polygeline 3.5.

Authors:  Saru Singh; Trupti D Shah; Ruchi Gupta; Preetween Kaur; Chiteshwar S Walia; Saroj Sehrawat
Journal:  Anesth Essays Res       Date:  2014 Sep-Dec

6.  Evaluation of antihypotensive techniques for cesarean section under spinal anesthesia: Rapid crystalloid hydration versus intravenous ephedrine.

Authors:  Kalpana Rajendra Kulkarni; Amruta Girish Naik; Sunetra Girish Deshpande
Journal:  Anesth Essays Res       Date:  2016 Sep-Dec

7.  Comparing prophylactic effect of phenylephrine and ephedrine on hypotension during spinal anesthesia for hip fracture surgery.

Authors:  Rahman Abbasivash; Shahryar Sane; Mitra Golmohammadi; Shahram Shokuhi; Fereshteh Danaye Toosi
Journal:  Adv Biomed Res       Date:  2016-10-26

8.  The effects of intravenous ephedrine during spinal anesthesia for cesarean delivery: a randomized controlled trial.

Authors:  Iclal Ozdemir Kol; Kenan Kaygusuz; Sinan Gursoy; Ali Cetin; Zeki Kahramanoglu; Fikret Ozkan; Caner Mimaroglu
Journal:  J Korean Med Sci       Date:  2009-09-23       Impact factor: 2.153

9.  Prevention of post-spinal hypotension using crystalloid, colloid and ephedrine with three different combinations: A double blind randomized study.

Authors:  Mitra Jabalameli; Hassan Ali Soltani; Jalal Hashemi; Shekoofe Behdad; Bahram Soleimani
Journal:  Adv Biomed Res       Date:  2012-08-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.